Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novo Nordisk And Shanghai Institute For Biological Sciences Jointly Set Up Research Center For Pre-diabetes

This article was originally published in PharmAsia News

Executive Summary

Novo Nordisk and Chinese Academy of Science's Shanghai Institute for Biological Sciences recently inaugurated a research center for pre-diabetes in Shanghai. China's first such facility, the joint venture will bring diabetes prevention to the pre-development stage of the disease. The center will initiate early monitoring and intervention in individuals who are at high risk of developing diabetes during the pre-clinical reversible stage. Individuals' samples and data will be collected during clinics and community follow-up. The research will focus on molecular mechanism and markers in the development of obesity and diabetes, as well as explore nutritional intervention methods and lifestyle changes to slow the disease. (Click here for more - Chinese Language)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC072437

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel